Kabra Drugs Limited has submitted a certificate for the quarter ended March 31, 2025, confirming compliance with SEBI regulations as provided by their Registrar and Share Transfer Agent, Skyline Financial Services.

This compliance reflects the company's adherence to operational standards required for maintaining shareholder records.

While this update is procedural, it reinforces the company's commitment to transparency and regulatory compliance.

Investors may view this as a positive outlook on governance practices, suggesting a stable operational framework that could support confidence in the company's management and future performance.